Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Thromb Haemost ; 124(7): 669-675, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38190984

RESUMEN

BACKGROUND: Polycythemia vera (PV) patients are classified as high or low thrombotic risk based on age and prior history of thrombosis. Despite adherence to treatment recommendations, vascular events remain frequent, leading us to question whether thrombotic risk stratification could be improved. We previously reported an association between thrombotic events and mutations in DTA genes (DNMT3A, TET2, and ASXL1). The objective of this study was to confirm this observation in a larger series of PV patients. METHODS: PV patients with a minimum follow-up of 3 years were recruited from 8 European centers. Medical history was searched for thrombotic event recorded at any time and next-generation sequencing carried out with a myeloid panel. Multivariable logistic regression evaluated the impact of variables on thrombotic risk. Kaplan-Meier thrombosis-free survival curves were compared by the log rank test. Associations in the total cohort were confirmed in a case-control study to exclude selection bias. RESULTS: Of the 136 patients recruited, 74 (56.1%) had a thrombotic event, with an incidence density of 2.83/100 person-years. In multivariable analysis, DTA mutation was a risk factor for thrombotic event, being predictive for shorter thrombosis-free survival in the whole cohort (p = 0.007), as well as in low-risk patients (p = 0.039) and older patients (p = 0.009), but not for patients with a prediagnostic event. A gender- and age-matched case-control study confirmed the increased risk of thrombotic event for PV patients with a DTA mutation. CONCLUSION: Our results support the use of molecular testing at diagnosis to help predict which PV patients are at higher risk of developing thrombosis.


Asunto(s)
ADN (Citosina-5-)-Metiltransferasas , ADN Metiltransferasa 3A , Proteínas de Unión al ADN , Dioxigenasas , Mutación , Policitemia Vera , Proteínas Proto-Oncogénicas , Proteínas Represoras , Trombosis , Humanos , Masculino , Femenino , Persona de Mediana Edad , Trombosis/genética , Factores de Riesgo , Anciano , Policitemia Vera/genética , Policitemia Vera/complicaciones , Proteínas Represoras/genética , Factores de Edad , Proteínas Proto-Oncogénicas/genética , ADN (Citosina-5-)-Metiltransferasas/genética , Proteínas de Unión al ADN/genética , Estudios de Casos y Controles , Adulto , Europa (Continente)/epidemiología , Incidencia , Predisposición Genética a la Enfermedad , Medición de Riesgo , Estimación de Kaplan-Meier , Anciano de 80 o más Años
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA